These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8913841)

  • 1. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Forsyth P; Cairncross G; Stewart D; Goodyear M; Wainman N; Eisenhauer E
    Invest New Drugs; 1996; 14(2):203-6. PubMed ID: 8913841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study.
    Sanson M; Napolitano M; Yaya R; Keime-Guibert F; Broët P; Hoang-Xuan K; Delattre JY
    J Neurooncol; 2000 Dec; 50(3):245-9. PubMed ID: 11263504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
    Dreyfuss AI; Clark JR; Norris CM; Rossi RM; Lucarini JW; Busse PM; Poulin MD; Thornhill L; Costello R; Posner MR
    J Clin Oncol; 1996 May; 14(5):1672-8. PubMed ID: 8622087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
    Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
    J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
    Fossella FV; Lee JS; Murphy WK; Lippman SM; Calayag M; Pang A; Chasen M; Shin DM; Glisson B; Benner S
    J Clin Oncol; 1994 Jun; 12(6):1238-44. PubMed ID: 7911160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
    Fossella FV; Lee JS; Shin DM; Calayag M; Huber M; Perez-Soler R; Murphy WK; Lippman S; Benner S; Glisson B
    J Clin Oncol; 1995 Mar; 13(3):645-51. PubMed ID: 7884425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
    Shapiro JD; Millward MJ; Rischin D; Davison JD; Michael M; Francis PA; Ganju V; Toner GC
    Aust N Z J Med; 1997 Feb; 27(1):40-4. PubMed ID: 9079252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of paclitaxel in patients with recurrent malignant glioma.
    Prados MD; Schold SC; Spence AM; Berger MS; McAllister LD; Mehta MP; Gilbert MR; Fulton D; Kuhn J; Lamborn K; Rector DJ; Chang SM
    J Clin Oncol; 1996 Aug; 14(8):2316-21. PubMed ID: 8708723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy.
    Einzig AI; Schuchter LM; Recio A; Coatsworth S; Rodriquez R; Wiernik PH
    Med Oncol; 1996 Jun; 13(2):111-7. PubMed ID: 9013474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
    Mertens WC; Eisenhauer EA; Jolivet J; Ernst S; Moore M; Muldal A
    Ann Oncol; 1994 Feb; 5(2):185-7. PubMed ID: 7910480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.
    Einzig AI; Neuberg D; Remick SC; Karp DD; O'Dwyer PJ; Stewart JA; Benson AB
    Med Oncol; 1996 Jun; 13(2):87-93. PubMed ID: 9013471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
    Adachi I; Watanabe T; Takashima S; Narabayashi M; Horikoshi N; Aoyama H; Taguchi T
    Br J Cancer; 1996 Jan; 73(2):210-6. PubMed ID: 8546908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
    Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R
    J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
    Trudeau ME; Eisenhauer EA; Higgins BP; Letendre F; Lofters WS; Norris BD; Vandenberg TA; Delorme F; Muldal AM
    J Clin Oncol; 1996 Feb; 14(2):422-8. PubMed ID: 8636752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
    Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
    Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
    Ravdin PM; Valero V
    Semin Oncol; 1995 Apr; 22(2 Suppl 4):17-21. PubMed ID: 7740326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
    Bedikian AY; Weiss GR; Legha SS; Burris HA; Eckardt JR; Jenkins J; Eton O; Buzaid AC; Smetzer L; Von Hoff DD
    J Clin Oncol; 1995 Dec; 13(12):2895-9. PubMed ID: 8523052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
    Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
    J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.